The Total number of records shown on this page is 81. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_5744	Virus nameVaccinia virus	Virus strainGLV-1h84	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of F14.5L gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 604.3mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5745	Virus nameVaccinia virus	Virus strainGLV-1h85	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA into F14.5L gene, TK gene at place of LacZ and gusA gene at place of HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 914mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5746	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 962.1mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5747	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1424.4mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5748	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1390.35mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5749	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 983.2mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5750	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1319.2mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5751	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1686.05mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5752	Virus nameVaccinia virus	Virus strainGLV-1h84	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of F14.5L gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 982mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5753	Virus nameVaccinia virus	Virus strainGLV-1h85	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA into F14.5L gene, TK gene at place of LacZ and gusA gene at place of HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 947.2mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5754	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1397.55mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5755	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1907.5mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5756	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1528.95mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5757	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 517.3mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5758	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1211.8mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5759	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1856.35mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5760	Virus nameVaccinia virus	Virus strainGLV-1h84	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of F14.5L gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 614.25mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5761	Virus nameVaccinia virus	Virus strainGLV-1h85	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA into F14.5L gene, TK gene at place of LacZ and gusA gene at place of HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 255.25mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5762	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 689.6mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5763	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1887.6mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5764	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1181.4mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5765	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 74.4mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5766	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 855.9mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5767	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1392mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5768	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 187.5mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5769	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 264.9mm compared to control 204.3 mm after 32 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5770	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 365.7mm compared to control 333.9 mm after 42 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5771	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 155.3mm compared to control 646.6 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5772	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 62mm compared to control 886.4 mm after 56 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5773	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (25mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 291.1mm compared to control 204.3 mm after 32 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5774	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (25mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 314.2mm compared to control 333.9 mm after 42 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5775	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (25mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 238.3mm compared to control 646.6 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5776	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (25mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 117.4mm compared to control 886.4 mm after 56 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5777	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 279.8mm compared to control 204.3 mm after 32 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5778	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 395.5mm compared to control 333.9 mm after 42 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5779	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 206.5mm compared to control 646.6 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5780	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 61mm compared to control 886.4 mm after 56 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5781	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 587.1mm compared to control 204.3 mm after 32 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5782	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 391.1mm compared to control 333.9 mm after 42 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5783	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 184mm compared to control 646.6 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5784	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cidofovir (100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 58mm compared to control 886.4 mm after 56 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5785	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 176.9 mm compared to control 278.1 after 53 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5786	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 598.8mm compared to control 755 after 63 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5787	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 668.4 mm compared to control 1169.9 after 69 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5788	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 896.6 mm compared to control 2512.7 after 77 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5789	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 298.8 after 41 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5790	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1448.3 after 55 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5791	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 2512.4 after 64 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5792	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 34.07 after 71 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5793	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 415.1 after 41 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5794	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1403.1 after 55 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5795	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1163.7 after 64 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5796	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 993 after 71 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5797	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 757.5 after 79 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5798	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 667 after 87 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5799	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 547 after 93 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5800	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 549 after 99 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5801	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 511 after 106 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5802	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 465.3 after 113 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5803	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 441.3 after 119 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5804	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 268.4 after 55 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5805	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 623.7 after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5806	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1232.5 after 70 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5807	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1277.05 after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5808	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1189.55 mm after 81 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5809	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 744.4mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5810	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 402.1 after 55 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5811	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1128.15 after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5812	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1485.05 after 70 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5813	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1599.35 after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5814	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1411.4mm after 81 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5815	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1040mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5816	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 906.75 mm after 96 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5885	Virus nameVaccinia virus	Virus strainMutant	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant in F2L gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5FC(100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenograft for LoVo cell	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1000mm compared to control 2500mm after 40 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9180150
IDOV_5886	Virus nameVaccinia virus	Virus strainMutant	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant in F2L gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5FC(100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenograft for HepG2	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1000mm compared to control 2500mm after 40 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9180150
IDOV_5896	Virus nameVaccinia virus	Virus strainVVTK-FCU1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDefective in J2R gene, expressing FCU1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon tumor cell line	Cell lineLoVo	Concentration of cell line3.0E+5 pfu	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.00001 MOI	In-vitro result60% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9687515
IDOV_5897	Virus nameVaccinia virus	Virus strainVVTK-FCU1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDefective in J2R gene, expressing FCU1 gene, defective in I4L gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon tumor cell line	Cell lineLoVo	Concentration of cell line3.0E+5 pfu	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.00001 MOI	In-vitro result58% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9687515
IDOV_5898	Virus nameVaccinia virus	Virus strainVVTK-FCU1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDefective in J2R gene, expressing FCU1 gene, defective in I4L gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5FU (100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismSwiss nude mice xenograft for LoVo cell line (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to nearly 1000mm compared to control 2400mm	Mode of deliveryIntravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9687515
IDOV_5899	Virus nameVaccinia virus	Virus strainVVTK-FCU1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDefective in J2R gene, expressing FCU1 gene, defective in F4L gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5FU (100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismSwiss nude mice xenograft for LoVo cell line (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 1000mm compared to control 2400mm	Mode of deliveryIntravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9687515
IDOV_5900	Virus nameVaccinia virus	Virus strainVVTK-FCU1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDefective in J2R gene, expressing FCU1 gene, defective in I4L gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismSwiss nude mice xenograft for U87MG(5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 500mm comapred to control 3500mm after 60 days	Mode of deliveryIntravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9687515
IDOV_5901	Virus nameVaccinia virus	Virus strainVVTK-FCU1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDefective in J2R gene, expressing FCU1 gene, defective in I4L gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5FU (100mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismSwiss nude mice xenograft for U87MG(5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 500mm comapred to control 3500mm after 60 days	Mode of deliveryIntravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9687515